2025
Présentation orale
de Pokomandy A, Petrakos N, Levy L, Danna S, Thomas R, Klein M, Baril JG, Durand D, Vachon ML, Pilarski R, Cox J, on behalf of the QHC team. 2023 HIV Cascade of care by specific groups in the Québec HIV Cohort. 20th 20th European AIDS Conference (EACS 2025), Paris, France, October 2025. Abstract #MeP18.1, oral presentation in moderated ePoster session.
Publications
Dolmatov M*, Petrakos NZ*, Moodie EEM, Thomas R, Durand M, Klein M, de Pokomandy A. (2025). “Regression-based estimation of optimal adaptive treatment strategies: Key methods.” In Biostatistics in Biopharmaceutical Research and Development: Clinical Trial Analysis, Volume 2. Available from: https://link.springer.com/chapter/10.1007/978-3-031-65937-9_12
*Co-first authors
2022
Présentations
de Pokomandy A. Cascade de soins du VIH: résultats de la Cohorte VIH du Québec. 29e Symposium sur les aspects cliniques de l’infection par le VIH du Programme National de Mentorat sur le VIH et les Hépatites. Montréal, Québec, 25 novembre 2022.
de Pokomandy A. Montreal City Case Study. Fast-Track Cities 2022. 13 October
2022. Available from: https://www.iapac.org/files/2022/10/FTC-2022-City-Case-Study-Montreal.pdf
de Pokomandy A. 2022 95-95-95 Targets Update – Prioritizing Equity to Close HIV Prevention and Treatment Gaps – Perspective from Montreal. AIDS 2022. Montréal, Québec and virtually, 28 July 2022.
Rapport court
de Pokomandy A, Chawla S, Levy L, Danna SM, Thomas R, Klein M, Baril JG, Durand M, Cox J. HIV cascade of care 2020 in the Québec HIV Cohort: a short report. FRQS Réseau SIDA-MI. 19 July 2022. Available from: https://www.reseausidami.quebec/hiv-cascade-of-care-2020-in-the-quebec-hiv-cohort-a-short-report/
2020
Publications
Sangaré MN, Baril JG, de Pokomandy A, Ferreira Guerra S, Carabali M, Laprise C, Thomas R, Klein M, Tremblay C, Roger M, Pexos C, Greenwald ZR, Machouf N, Durand M, Hardy I, Dakouo M, Trevisan A, Laporte L, Schnitzer ME and Trottier H. Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World Data. Open Forum Infectious Diseases. 2020;7(11): ofaa404. doi: 10.1093/ofid/ofaa404. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7654378/
Sangaré MN, Baril JG, de Pokomandy A, Laprise C, Deshaies C, Klein M, Thomas R, Tremblay C, Roger M, Pexos C, Greenwald Z, Machouf N, Durand M, Hardy I, Dakouo M, Laporte L, Trottier H. Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV. Medicine. 2020;99(47):e23335. doi: 10.1097/MD.0000000000023335. Available from: https://journals.lww.com/md-journal/fulltext/2020/11200/impact_of_previous_hiv_resistance_and_virologic.88.aspx
2018
Résumé exécutif
Linthwaite B, Sangare N, Trottier H, Baril JG, Durand M, Klein M, Machouf N, Pexos C, Thomas R, Tremblay C, Vassal AF, and Cox J. In-care HIV cascades for the city of Montreal: Data from the Cohorte Montréalaise. Executive Summary. 29 November 2018. Available from: https://www.researchgate.net/publication/362504800_In-care_HIV_cascades_for_the_city_of_Montreal_Data_from_the_Cohorte_Montrealaise_–_Executive_Summary
Cohorte VIH du Québec 